Newsroom

The 13th edition of the Cajal Conference 2026, organized by the Sociedad Española de Neurociencia, was held last week in Cádiz. The meeting, which included members of the Institute on the organizing committee, served to share advances, foster scientific debate, and promote new collaborations within the neuroscience community.

Over the weekend of April 18–19, the Festa de la Ciència in Barcelona took place, and both the Institute and Neurodocs joined in with a wide range of activities!

A study by the University of Canterbury, in collaboration with the Institute, reveals how a disabled kea without an upper beak became the dominant male in his group through a unique fighting strategy.

Once again, researchers from the Institute will take part in the Barcelona Science Festival, which will be held on April 18 and 19.

The European Medicines Agency (EMA) has designated as an orphan drug a compound based on the bioactive lipid molecule Maresin-1 (MaR1), currently being investigated by a research team from the UAB for the treatment of spinal cord injuries.

To mark Brain Awareness Week, the Institute of Neuroscience and the Neurodocs doctoral association are organizing Cervella’t, a series of online outreach talks that will bring neuroscience research closer to the general public.

Different research groups at the Institute are seeking a highly motivated fellow to apply for the Marie Skłodowska-Curie Actions European Postdoctoral Fellowship (EPF) 2026.

A study coordinated by the Institut de Neurociències of the Universitat Autònoma de Barcelona proposes a new treatment for glioblastoma, the most aggressive brain tumor. The approach involves patches tested in cell cultures and in excised pig brains that induce a high level of cellular oxidation in a local and controlled manner, thereby minimizing potential systemic side effects. Read the article

By analyzing tissue from patients with Parkinson’s disease, and animal and cellular models of the disease, a research team led by Dr Carlos Barcia has shown that the main immune cells of the brain become reactive and overexpress certain receptors that promote the elimination of dopaminergic neurons, even when these neurons are still functional. The study points to a new immunotherapy approach that could help preserve viable neurons in people with this diagnosis.. Read the article

The work reveals that these metabolites bind to specific protein domains and act as a shield against modifications to their structure.